ArriVent BioPharma, Inc.
AVBPArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing and commercializing differentiated therapies for cancer, with a primary emphasis on solid tumors.
Earnings
Next report
Aug 14, 2026 (In 2 weeks)Financials
Q1 2026Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing and commercializing differentiated therapies for cancer, with a primary emphasis on solid tumors. The company's lead strategy involves advancing firmonertinib, a mutant-selective tyrosine kinase inhibitor, to address underserved segments of the non-small cell lung cancer (NSCLC) market. By leveraging a global network for business development, the company aims to build a pipeline of next-generation oncology assets, including antibody drug conjugates.
A clinical-stage developer targeting uncommon EGFR mutations (exon 20 and PACC) where current standard-of-care therapies like third-generation TKIs show limited efficacy.
Questions, answered.
- What is ArriVent BioPharma, Inc.'s market cap?
- ArriVent BioPharma, Inc. (AVBP) has a market capitalization of $1.4B and trades on NASDAQ.
- Who are ArriVent BioPharma, Inc.'s competitors?
- ArriVent BioPharma, Inc.'s key competitors include Johnson & Johnson, Nuvation Bio Inc., Erasca, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does ArriVent BioPharma, Inc. partner with?
- ArriVent BioPharma, Inc.'s notable partners include Shanghai Allist Pharmaceuticals, Co. Ltd, Aarvik Therapeutics, Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and others.
- Where is ArriVent BioPharma, Inc. headquartered?
- ArriVent BioPharma, Inc. is headquartered in United States of America and employs approximately 40 people. It has been publicly traded since 2024.